BACKGROUND: A prognostic model for @entity1 with metastatic @entity189 ( @entity189 ) progressing after @entity902 -based therapy was constructed from data from the phase III @entity24986 trial. However, prognostic information for @entity1 treated with other regimens is limited. MATERIALS AND METHODS: We pooled individual @entity1 data from 7 second-line studies and analyzed the influence of factors of interest on overall survival (OS) through univariate and multivariate analysis. A prognostic model was constructed, and data from an independent series were used for validation. RESULTS: The data from 193 @entity1 were pooled. The second-line chemotherapy regimen was single-agent @entity3907 in 54 @entity1 (28%), a @entity902 -based combination in 47 (24%), and a non- @entity902 combination in 92 (48%). On multivariate analysis, Eastern Cooperative Oncology Group performance status  >=  1, hemoglobin  < 10 g/dL, and metastatic patterns other than lymph node-only metastasis emerged as independent adverse prognostic factors. @entity1 with all 3 factors (poor risk), 1 to 2 factors (intermediate risk), and no factors (good risk) had a median OS of 3.1, 8.7, and 16.5 months, respectively (P  < .0001). The corresponding median OS for the validation series (n  =  44) was 3.3, 8.1, and 13.3 months (P  = .023). Furthermore, @entity902 -based regimens were independently associated with an OS benefit compared with other regimens (hazard ratio, 0.31; 95% confidence interval, 0.18-0.53; P  < .0001). CONCLUSION: We have proposed and validated a prognostic model for @entity1 with metastatic @entity189 who were eligible for second-line therapy. The proposed model could prove helpful for risk stratification. Furthermore, our data suggest that testing second-line @entity902 -based regimens in randomized trials is warranted.

Second-Line Chemotherapy for Metastatic XXXX : Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity24986 :: ('MESH:C111217', 'Chemical') :: ['vinflunine'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma', 'UC'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity189 :: (MESH:D002277,Disease) :: ['Urothelial Carcinoma']
